Dedicated solely to molecular diagnostics, DiagCor was established in 2006. The global leader in
flow-through hybridization technology, we offer a range of products, solutions and services related to RNA and DNA analysis.
Hybridization is an essential step in medium resolution DNA and RNA analysis. DiagCor’s flexible flow-through hybridization platform simplifies lab workflow and reduces overheads.
We have developed our core technology into a range of molecular and cytogenetic services. Our products and services spans prenatal diagnosis, genetic testing, parentage investigation, cancer testing and infectious disease identification.
Our research and development pipeline includes tests in other areas such as cancer biomarker identification and pharmacogenomics.
DiagCor offers a complete platform for commercial and clinical MDx diagnosis.
We have helped to establish high-capability MDx labs all around the world. We serve clinical diagnostic services markets in Latin America, Europe, Middle East and South East Asia. Our customers enjoy extensive support from our team of dedicated MDx specialists.
Our partnerships with research institutions and MDx practitioners help to keep us on the forefront of practical bioscience.
Molecular diagnosis has recently been described as the fastest growing segment of the in vitro diagnostics (IVD) industry. DiagCor translates cutting-edge MDx research into practical, proven market applications.
We are vertically equipped to manage the entire MDx development process. Our operations span primary research, clinical and market studies, to manufacturing, commercialization, global distribution and ongoing support.
Global demand for MDx products and services is growing fast. Factors driving this growth include:
DiagCor is structured to innovate in MDx and encourages close cooperation between our R&D and production, commercial laboratory and marketing teams.
We stay at the forefront of developments in bioscience by continually investing in systems, technology and talent.
By combining R&D know-how with practical commercial lab experience we can quickly develop proven products with strong market potential.
DiagCor is led, guided and operated by a respected group of biotech scientists and executives with an extraordinary depth and breadth of experience.
The combined talents of our team enable our company to stay on the forefront of developments in MDx innovations. Qualified and experienced individuals in the life science sector are invited to inquire about working with DiagCor.
Dr Joseph W O Tam PhD
Chairman / CEO
Professor Joseph Tam is a research pioneer with over 30 years of teaching and research experience in the biotechnology and diagnostics sector. Professor Tam is a Visiting Professor at UCSF, Baylor Medical College and Medical College of Georgia, Scientist of National Institute of Health, Associate Professor and Honorary Associate Professor of Medical Faculty of Hong Kong University. He is the Founder and President of the Hong Kong Biochemistry Association.
With the support of UNESCO, Professor Tam organized and trained the first group of scientists in China and Asia Pacific Regions on recombinant DNA research in 1983. During his years of teaching and research at HKU, Professor Tam invented and patented the “flow-through hybridization” technology.
Following his passion for Molecular Diagnostics, Professor Tam established DiagCor Bioscience Incorporated Limited in 2006. He strives to influence and inspire the talent of Hong Kong’s next generation in biotechnology.
Dr Joseph Chow PhD
General Manager / R&D Manager
Dr Joseph Chow holds a PhD at the University of Hong Kong. He commenced his career as a medical technologist at Singapore General Hospital, where he received extensive training in the field of Hematology. He joined Professor Joseph Tam’s lab at the University of Hong Kong in 2000. While there, Dr Chow co-developed flow-through hybridization-based diagnostic tests, such as β-Thalassemia and Hepatitis B Virus with Professor Tam. Over the years, he gained broad molecular experience in the key areas of real-time PCR, Chromosomal Conformation Capture (3C) technology, molecular expression studies, and reversed dot-blot based technology. In 2011, Dr Chow completed his training for AmpFlSTR (Applied Biosystems), and provided Chinese gene authentication and human identification using STR and SNP analysis.
Dr Chow joined DiagCor as the R&D Manager in August 2006 and worked in that position until 2014. He and his team had developed over 20 flow-through hybridization diagnostic instrument and kits, established over 50 clinical diagnostic projects, and published articles on technology analysis and scientific journals. He now owns over 20 patents in various inventions.
Dr Joseph Chow is currently the General Manager of Hong Kong and GuangZhou DiagCor, a hundred-staff company with more than 10 post-docs and 30 Masters graduates working under his leadership. In 2014, with Dr Chow’s rich experience and knowledge in clinical translational medicine, he was invited by the Biotechnology Research Institute, Chinese Academy of Agricultural Sciences in taking up the post in product translational development. Dr Chow is also concurrently the external research grant auditor of the City University of Hong Kong, further exemplifying his profession in the industry.
DiagCor MDx services and solutions are available worldwide via our rapidly expanding network of partners and distributors. We also offer fast support from our Hong Kong headquarters.
DiagCor works with commercial, institutional and governmental organizations across the world to bring MDx understanding and benefits to as many people as possible.
Chinese University of Hong Kong
City University of Hong Kong
Mammalian species identification in food with flow-through hybridization
University of Hong Kong
HPV screening in an Asian population
Hong Kong Society of Molecular Diagnostic Sciences
Independent evaluation of tuberculosis diagnostic kit
We work with the following commercial organizations and encourage bioscience executives across the world to contact us to discuss how we might collaborate.
We work with the following NGOs as part of our initiatives to provide people with better healthcare.